Advertisement

Kaposi’s Sarcoma

  • Alice U. Amani
  • Constantin E. Orfanos
Chapter

Abstract

Kaposi’s sarcoma (KS) has been originally described by Kaposi as an idiopathic multiple neoplasm of the skin composed of proliferating vessels and spindle-shaped cells. Its origin has been an issue of debate for long; there is evidence to believe that the tumor is derived from endothelial cells, particularly from lymphatic endothelium. There are four types of KS known today, based on their occurrence and the accompanying clinicopathological data. The classic KS has been first seen and described by Moritz Kaposi in Europe in 1872, an endemic type was recognized in 1960s in sub-Saharan Africa, a KS variant associated with immunosuppressive therapies (iatrogenic) has been reported by various groups in Western countries particularly in organ transplant patients, and the HIV-associated KS type, also called epidemic, first appeared in the United States in 1981. Human herpesvirus 8 (HHV-8) is considered as an etiological agent for all variants. Primary effusion lymphoma and multicentric Castleman’s disease are also linked with this virus.

References

  1. 1.
    GLOBOCAN. Estimated cancer incidence, Mortality and Prevalence Worldwide, 2012. www.globocan.iarc.fr. Accessed 5 Nov 2014.
  2. 2.
    Lodi S, Guiguet M, Costagliola D, et al. Kaposi sarcoma incidence and survival among. HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102:784–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cook-Mozaffari P, Newton R, Baral V, et al. The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78:1521–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    DalMaso L, Serraino D, Franceschi S. Epidemiology of AIDS related tumours in developed and developing countries. Eur J Cancer. 2001;37:1188–201.CrossRefGoogle Scholar
  5. 5.
    Onyango JF, Njiru A. Kaposis sarcoma in a Nairobi hospital. East Afr Med J. 2004;81:120–3.PubMedGoogle Scholar
  6. 6.
    Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpes virus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196:199–207.CrossRefPubMedGoogle Scholar
  7. 7.
    Geraminejad P, Memar O, Aronson I, et al. Kaposi’s sarcoma and other manifestations of human herpes virus 8. J Am Acad Dermatol. 2002;47:641–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Pérez C, Tous M, Gallego S, et al. Seroprevalence of human herpesvirus-8 in blood donors from different geographical regions of Argentina, Brazil, and Chile. J Med Virol. 2004;72:661–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Mohanna S, Maco V, Bravo F, et al. Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpes virus 8 in South America: a critical review of an old disease. Int J Infect Dis. 2005;9:239–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Tappero JW, Conant MA, Wolfe SF, et al. Kaposi’s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol. 1993;28:371–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Orfanos CE, Husak R, Wölfer U, Garbe C. Kaposi’s sarcoma: a reevaluation. Recent Results Cancer Res. 1995;139:275–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Wamburu G, Masenga EJ, Moshi EZ, et al. HIV-associated and non-HIV associated types of Kaposi's sarcoma in an African population in Tanzania. Status of immune suppression and HHV-8 seroprevalence. Eur J Dermatol. 2006;16:677–82.PubMedGoogle Scholar
  13. 13.
    Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–38.CrossRefPubMedGoogle Scholar
  14. 14.
    Brambilla L, Bellinvia A, Tourlaki A, et al. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. 2009;162:854–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Krown SE. Acquired immunodeficiency syndrome associated Kaposi’s sarcoma. Biology and management. Med Clin North Am. 1997;81:471–94.CrossRefPubMedGoogle Scholar
  16. 16.
    Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood. 2007;110:4165–71.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pfrommer C, Tebbe B, Tidona CA, et al. Progressive HHV-8-positive classic Kaposi's sarcoma: rapid response to interferon alpha-2a but persistence of HHV-8 DNA sequences in lesional skin. Br J Dermatol. 1998;139:516–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Vanni T, Sprinz E. Machado MW et al Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev. 2006;32:445–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Gascon P, Schwartz RA. Kaposi’s sarcoma. New treatment modalities. Dermatol Clin. 2000;18:169–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Bower M, Weir J, Francis N. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS. 2009;23:1701–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8:167–76.Google Scholar
  22. 22.
    Qunibi WY, Barri Y, Alfurayh O, et al. Kaposi’s sarcoma in renal transplant recipients: a report on 26 cases from a single institution. Transplant Proc. 1993;25:1402–5.Google Scholar
  23. 23.
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi sarcoma in renal-transplant patients. N Engl J Med. 2005;352:1317–23.Google Scholar
  24. 24.
    Koon HB, Fingleton B, Lee JY, et al. Phase II AIDS malignancy consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr. 2011;56:64–8.Google Scholar
  25. 25.
    Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with post-transplant Kaposi’s sarcoma. Am J Transplant. 2006;6:2164–8.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service de DermatologieCentre Hospitalier UniversitaireKigaliRwanda
  2. 2.The Free University of Berlin, Medical School CharitéBerlinGermany

Personalised recommendations